Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults | Zendy

Joanne M. Langley | Zendy; Louise Frenette | Zendy; Linda Ferguson | Zendy; Dennis Riff | Zendy; Eric Sheldon | Zendy; George Risi | Zendy; Casey Johnson | Zendy; Ping Li | Zendy; Richard T. Kenney | Zendy; Bruce L. Innis | Zendy; Louis Fries | Zendy

Open Access

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

Author(s) -

Joanne M. Langley,

Louise Frenette,

Linda Ferguson,

Dennis Riff,

Eric Sheldon,

George Risi,

Casey Johnson,

Ping Li,

Richard T. Kenney,

Bruce L. Innis,

Louis Fries

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/652701

Subject(s) - immunogenicity , reactogenicity , adjuvant , medicine , influenza a virus subtype h5n1 , hemagglutinin (influenza) , vaccination , virology , antigen , trivalent influenza vaccine , influenza vaccine , immunology , virus

The tocopherol-based oil-in-water emulsion adjuvant system family (AS03) improves antigen sparing with split-virion H5N1 influenza vaccines, representing an important development for pandemic preparedness. In this phase 1/2 randomized, controlled, observer-blinded study in 680 adults, we assessed the immunogenicity and safety of A/Indonesia/5/05 H5N1 (IBCDC-RG2, clade 2.1) prepandemic candidate vaccines produced at 2 separate manufacturing sites.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research